文献速递血脂与心血管预防

中年期非高密度脂蛋白胆固醇轨迹对心血管预防的意义

Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

基于Framingham后代研究2516名25-40岁无心血管病和糖尿病参与者,建模非HDL-C在平均32.6年随访中的轨迹。青年期非HDL-C水平高度预测后续水平,≥160 mg/dl者80%维持高位,25年心血管病风险22.6% vs 低水平者6.4%。提示40岁前早期血脂监测可识别长期高风险个体。

要点

  • 青年期非HDL-C≥160 mg/dl者80%在25年后仍维持高位。
  • 青年期非HDL-C≥160 mg/dl者25年心血管病风险22.6%,<130 mg/dl者仅6.4%。
  • 40岁前两次非HDL-C测量可可靠区分长期高/低风险轨迹。

核心结论

  • 青年期非HDL-C升高者多数终身维持高位,长期心血管病风险显著增加。
  • 40岁前早期血脂监测可识别 lifetime 高脂水平及高心血管病风险个体。

研究设计与样本

  • Framingham后代研究样本2516名25-40岁无心血管病和糖尿病参与者,平均随访32.6年,共8次检查。
  • 采用基于组别的方法建模非HDL-C轨迹,Kaplan-Meier分析评估25-30年心血管病风险。

主要发现

  • 非HDL-C轨迹在30年生命周期中总体稳定,青年期均值高度预测后期水平。
  • 首次两次检查非HDL-C≥160 mg/dl者80%在后续25年仍维持高位;<130 mg/dl者88%仍低于160 mg/dl。
  • 青年期非HDL-C≥160 mg/dl者25年心血管病风险22.6%,<130 mg/dl者6.4%。

关键数值与推荐

  • 高非HDL-C定义为首次两次检查平均≥160 mg/dl,低非HDL-C定义为<130 mg/dl。
  • 接受调脂治疗者的非HDL-C水平经非参数算法校正。

临床怎么用

  • 建议40岁前进行血脂监测,通过两次非HDL-C测量识别长期高心血管病风险个体。
  • 早期识别高风险个体可促进医患讨论中年早期预防性降脂治疗的潜在获益。

局限性

  • 研究基于Framingham后代研究样本,结果外推需谨慎。
  • 调脂治疗者的血脂水平经非参数算法校正,可能引入残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended elevations of non-high-density lipoprotein cholesterol (non-HDL-C) across a lifespan are associated with increased risk of cardiovascular disease (CVD). However, optimal testing intervals to identify individuals with high lipid-related CVD risk are unknown. OBJECTIVES: This study determined the extent to which lipid levels in young adulthood predict future lipid trajectories and associated long-term CVD risk. METHODS: A sample of 2,516 Framingham Offspring study participants 25 to 40 years of age free of CVD and diabetes had their non-HDL-C progression modeled over 8 study examinations (mean follow-up 32.6 years) using group-based methods. CVD risk based on 25 to 30 years of follow-up was evaluated using Kaplan-Meier analyses for those with mean non-HDL-C ≥160 mg/dl ("high") and <130 mg/dl ("low") at the first 2 examinations. Levels of non-HDL-C for participants on lipid treatment were adjusted by nonparametric algorithm. RESULTS: The trajectories of the lipid levels were generally stable over the 30-year life course; mean non-HDL-C measured in young adulthood were highly predictive of levels later in life. Individuals could be reliably assigned to high and low non-HDL-C groups based on 2 measurements collected between 25 to 40 years of age. Overall, 80% of those with non-HDL-C ≥160 mg/dl at the first 2 exams remained in the high group on subsequent 25-year testing, whereas 88% of those with non-HDL-C <130 mg/dl remained below 160 mg/dl. Those with high non-HDL-C in young adulthood had a 22.6% risk of CVD in the next 25 years as compared with a 6.4% risk in those with low non-HDL-C. CONCLUSIONS: Most adults with elevated non-HDL-C early in life continue to have high non-HDL-C over their life course, leading to significantly increased risk of CVD. The results demonstrate that early lipid monitoring before 40 years of age would identify a majority of those with a high likelihood for lifetime elevated lipid levels who also have a high long-term risk for CVD. This information could facilitate informed patient-provider discussion about the potential benefits of preventive lipid-lowering efforts during the early midlife period.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Pencina KM, Thanassoulis G, Wilkins JT, et al. Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention. J Am Coll Cardiol. 2019. PMID: 31272554. doi:10.1016/j.jacc.2019.04.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。